abstract: Vascular endothelial growth factor (VEGF) and its soluble receptor (sVEGFR-1) are key regulators in human ovarian angiogenesis. Produced by granulosa and ovarian theca interna cells, VEGF promotes blood vessel growth during follicular development and corpus luteum formation, whereas sVEGFR-1, which is secreted by endothelial cells, functions as an antagonist to VEGF activity by binding it. In order to gain further insights into the regulatory mechanisms of ovarian angiogenesis, the aim of the present study was to analyze the influence of tissue inhibitor of metalloproteinase 1 (TIMP-1), which is actively involved in the degradation and remodeling of the extracellular matrix, on sVEGFR-1 secretion of cultured human umbilical vein endothelial cells. sVEGFR-1 production was determined in the culture supernatant by Sandwich-ELISA. We showed that TIMP-1 produced by human granulosa cells and recombinant human TIMP-1 both significantly increased the production of sVEGFR-1 in endothelial cells. Also, the down-regulation of TIMP-1 expression by RNA interference resulted in a significant reduction of endothelial sVEGFR-1 secretion into the culture medium. Furthermore, TIMP-1 weakly inhibited proliferation of VEGF-stimulated endothelial cells. In conclusion, our results provide evidence that TIMP-1 increases the production of sVEGFR-1 in endothelial cells and thus may reduce VEGF bioavailability, leading to reduced blood vessel growth in the ovary.
Introduction
Angiogenesis, the development of new blood vessels from pre-existing microvasculature, is rarely found in adults except under pathological conditions such as wound healing and tumor growth. However, under physiological conditions, it occurs regularly in the female reproductive system during the menstrual cycle as part of follicular development, corpus luteum formation and endometrial proliferation in the uterus (Fraser and Lunn, 2000; Plendl, 2000; Wulff et al., 2004; Gruemmer et al., 2005a) . Angiogenesis also occurs in pregnancy to ensure optimal blastocyst implantation as well as placental and early embryonic development (Reynolds and Redmer, 2001; Sherer and Abulafia, 2001; Matsumoto et al., 2007) . During angiogenesis, the basement membrane of existing blood vessels breaks down and this is followed by the migration of endothelial cells into the interstitial space as directed by angiogenic stimuli. Afterwards, the endothelial cells start to proliferate and differentiate under promotion of angiogenic factors. During the final steps, the new capillaries are stabilized by pericytes and then may differentiate into arterioles and venules by acquiring layers of smooth muscle cells (Plendl, 2000; Fraser and Lunn, 2001; Douglas et al., 2005; Kaczmarek et al., 2005) .
The ovarian cycle is characterized by follicular growth as well as by the formation and regression of the corpus luteum. Although angiogenesis is restricted to the theca cell layer during follicular development, a dense capillary network is formed in the growing corpus luteum after the collapse of the basement membrane that accompanies ovulation (Fraser and Lunn, 2001; Fraser, 2006) . In contrary to pathological conditions, the angiogenic process in the female reproductive system has to be tightly regulated. Among many regulators of ovarian angiogenesis, vascular endothelial growth factor (VEGF) plays a pivotal role (Dickson et al., 2001; Kaczmarek et al., 2005) .
VEGF is a basic, heparin-binding homodimeric glycoprotein with a molecular weight range of 34 -45 kDa and a direct inducer of angiogenesis. Five isoforms have been identified in humans so far, each generated by alternative splicing of a single mRNA and resulting in proteins of 121, 145, 165, 189 and 206 amino acids in length (Geva and Jaffe, 2000; Robak et al., 2003) . It binds specifically to two membrane receptors located on endothelial cells: VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Although VEGFR-1 is required for normal blood vessel development during embryogenesis, VEGFR-2 is the predominant receptor in angiogenic signaling regulating endothelial cell migration, proliferation, differentiation and survival (Cébe-Suarez et al., 2006) . In addition, a soluble, truncated form of VEGFR-1 (sVEGFR-1, sFlt-1) is known and is formed by alternative splicing of the precursor mRNA. It is secreted from endothelial cells into their vicinity and into circulation and it reduces the bioavailability of VEGF by binding to this growth factor (Charnock-Jones, 2002; Pau et al., 2006) . The initial step in angiogenesis is the breakdown of the basement membrane as part of the extracellular matrix (ECM). The key proteolytic enzymes involved in the degradation of ECM proteins are the matrix metalloproteinases (MMPs) (Duncan, 2000) . These are a family of secreted and membrane-bound endopeptidases consisting of more than 20 members. MMPs contribute to angiogenesis not only by degrading ECM components but also by releasing ECM-bound proangiogenic factors such as VEGF and thus modulating its bioavailability (Rundhaug, 2003; Lee et al., 2005a) . The expression and activity of MMPs is partly controlled by the tissue inhibitors of metalloproteinases (TIMPs). The four known human TIMPs are secreted low-molecular-weight proteins (21 -28.5 kDa) that inhibit MMP activity by binding to the catalytic domain of the active enzyme (Reed et al., 2003; Stetler-Stevenson and Seo, 2005) .
Although TIMPs are principally viewed as MMP inhibitors, other biological functions are emerging. These include potential roles as growth factors, survival factors, growth inhibitors and inhibitors of angiogenesis (Mannello and Gazzanelli, 2001; Stetler-Stevenson and Seo, 2005; Chirco et al., 2006; Stetler-Stevenson, 2008) . Studies in recent years have revealed that the biological effects of TIMPs are mediated either, indirectly, by MMP-dependent or, directly, by MMP-independent mechanisms (Baker et al., 1998; Akahane et al., 2004; Chirco et al., 2006) .
Several proteins such as basic fibroblast growth factor (bFGF), thrombin and granulocyte macrophage colony-stimulating factor (GM-CSF) as well as hypoxic conditions are known to induce the secretion of sVEGFR-1 (Barleon et al., 2001; Eubank et al., 2004; Lockwood et al., 2007; Munaut et al., 2008) , whereas others such as MMP-7 can cause the degradation of this receptor (Ito et al., 2009) . However, the regulation of sVEGFR-1 production in endothelial cells is still poorly understood. In order to gain further insights into this process, the aim of our research was to investigate the influence of TIMP-1 on sVEGFR-1 secretion from human endothelial cells and thus on ovarian angiogenesis.
Materials and Methods

Subjects
Follicular fluid and granulosa cells were obtained during oocyte retrieval and blood samples were collected during routine examinations from 78 FSH-treated women aged 33.2 + 4.7 years undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment at the Clinic of Gynecological Endocrinology and Reproductive Medicine of the Medical Faculty of the RWTH Aachen University, Germany. The etiologies of infertility were andrological abnormalities (57), tubal diseases (11), idiopathical causes (7) and endometriosis (3). Ovarian stimulation and oocyte retrieval have been described previously (Neulen et al., 2001) . The experimental design was approved by the local ethics committee of the RWTH Aachen University and all patients gave written informed consent.
Granulosa cell culture
After oocyte removal, follicular aspirates were centrifuged for 5 min at 200g to separate granulosa cells from follicular fluids. The individual follicular fluids were frozen at 2208C. Granulosa cells from each patient were isolated as described before (Gruemmer et al., 2005b) with the exception of using serum-free medium M199 supplemented only with 5 mM L-glutamine and 10 000 IU/10 000 mg/ml penicillin/streptomycin (all Biochrom AG, Berlin, Germany). Briefly, cells separated from follicular fluid were washed several times with Ca 2þ -and Mg 2þ -free phosphatebuffered saline (PBS w/o) (Biochrom AG) and pelleted. They were then purified over a 50% percoll gradient purchased from Biochrom AG for 10 min at 780g and washed once with PBS w/o afterwards. The purified granulosa cells were digested with 20 IU bovine testicular hyaluronidase (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) for 5 min at 378C. After enzyme dilution with medium M199, they were centrifuged, resuspended and counted. Isolated granulosa cells were plated in a 24-well format (Becton -Dickinson Labware, Franklin Lakes, NJ, USA) at a concentration of 200 000 cells/well in M199 which was removed 24 h after cell preparation. Granulosa cells were then cultured in 750 ml M199 per well at 378C and 5% CO 2 until the conditioned medium was collected after 4 days and stored at 2208C until further processing.
Granulosa cell concentrates
After thawing and pelleting of any precipitated material or cells for 5 min at 48C and 3900g, conditioned media from 22 patients per experiment were combined and concentrated by using centrifugal spin devices with 50 kDa molecular weight cut-offs (Millipore GmbH, Eschborn, Germany) at 48C and 3900g. The ultra-filter flow through was frozen at 2208C until further use. Conditioned medium was concentrated either 30-fold for direct SDS gel electrophoresis or 60-fold for the following experiment. Granulosa cell concentrate (GCC) was treated with concanavalin A lectin (ConA), coupled to Sepharose 4B (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and equilibrated with 20 mM Tris -HCl, pH 7.4, 500 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 and 1 mM MnCl 2 , for 3 h at 48C. Afterwards, ConA was removed by two successive centrifugations for 5 min at 50g each. Proteins bound to immobilized lectin were eluted for 3 h at 48C using equilibration buffer containing 1 M methyl a-D-mannopyranoside (Sigma-Aldrich Chemie GmbH) and loaded unto a preparative SDS gel.
Blood samples
To separate the clot from the serum, patients' blood was centrifuged for 5 min at 48C and 1750g. Clear serum was removed and frozen individually at 2208C until further use.
SDS gel electrophoresis
SDS -PAGE was performed according to Laemmli (1970) . Pure 30-fold enriched GCC, ConA eluate and prestained protein marker (Fermentas GmbH, St. Leon-Rot, Germany) were loaded onto a preparative 15% SDS gel. After protein separation, bands were visualized with Coomassie R250 and excised in a keratin-free environment using a laminar flow hood. Contained proteins were then tryptic digested and identified by mass spectrometry and mascot search.
Endothelial cell culture
Cryopreserved pooled human umbilical vein endothelial cells (HUVECs) at passage 1 purchased from Lonza GmbH (Wuppertal, Germany) were grown in endothelial cell culture medium EBM-2 containing 2% FCS and supplements (Lonza GmbH) as described before (Motejlek et al., 2006) . HUVECs were plated in a 24-well format at a density of 100 000 cells/ well and culture medium was changed 24 h after cell preparation. The endothelial cells were then cultured either in 920 ml serum-free EBM-2 medium alone or in serum-free EBM-2 containing either 60-fold enriched untreated GCC, treated GCC, flow through or increasing amounts of recombinant human TIMP-1 (R&D Systems, Minneapolis, MN, USA), respectively. After 4 days incubation at 378C and 5% CO 2 , supernatants were collected and stored at 2208C until further use.
ELISA assays
TIMP-1 concentration was examined in patient's follicular fluid and blood serum as well as in conditioned medium derived from granulosa and endothelial cells by ELISA from RayBiotech Inc. (Norcross, GA, USA). For sVEGFR-1 quantification in the HUVEC supernatant, however, ELISA assays were purchased from Bender MedSystems GmbH (Vienna, Austria). Both ELISA types were accomplished according to the manufacturer's protocol and analyzed by using the automated microplate reader HTII (Anthos Labtec Instruments Co., Salzburg, Austria) set at 450 nm. Intra-and inter-assay coefficiencies were CV , 5.1% and CV , 5.4% for the sVEGFR-1 ELISA but CV , 10% and CV , 12% for the TIMP-1 ELISA, respectively. All analyses were performed in duplicate for each sample.
Proliferation/inhibition assay
HUVECs were plated in a 24-well format at a concentration of 25 000 cells/well in EBM-2 which was removed 24 h after cell preparation and replaced by EBM-2 medium containing FCS but no supplements, except the antibiotic. The cells were then cultured either in 625 ml EBM-2 alone, in EBM-2 containing 10 ng/ml VEGF (Sigma-Aldrich Chemie GmbH) or in culture medium supplemented with 10 ng/ml VEGF and co-incubated 36 h later with 30 ng/ml recombinant human TIMP-1, respectively. After 72 h incubation at 378C and 5% CO 2 , a part of the supernatants was collected and stored at 2208C for later sVEGFR-1 quantification, whereas the remaining cultures were used for performing the XTT proliferation assay purchased from Roche Diagnostics GmbH (Mannheim, Germany) according to the manufacturer's protocol. This assay is based on the cleavage of the yellow tetrazolium salt XTT to form an orange formazan dye by metabolic active cells. This conversion only occurs in viable cells. An increase in the number of living cells results in an increase in the overall activity of mitochondrial dehydrogenases and therefore correlates to the amount of orange formazan formed. After addition of the labeling mixture, cultures were incubated for 2 h at 378C and 5% CO 2 . Absorbance of the samples was then measured in a 96-well format by using the automated microplate reader HTII set at 492 nm.
RNA interference
HUVECs were plated in a 24-well format at a density of 50 000 cells/well. After 24 h, cells were transfected in a total volume of 500 ml EBM-2 with serum-free Opti-MEM I medium (Invitrogen BV, Leek, The Netherlands) containing Lipofectamine RNAiMAX (Invitrogen BV) and either genespecific HuSH 29mer shRNA constructs (OriGene Technologies Inc., Rockville, MD, USA) targeting human TIMP-1, expression vector alone or plasmid containing a non-effective green fluorescent protein (GFP) sequence, respectively, according to the manufacturer's protocol. After 4 days incubation at 378C and 5% CO 2 , supernatants were harvested and stored at 2208C until TIMP-1 and sVEGFR-1 quantification by ELISA assay.
Statistical analysis
Statistical analysis was performed with GraphPad Prism, version 4.0, purchased from GraphPad Software Inc. (San Diego, CA, USA), using one-way ANOVA followed by Tukey's post test. Results are shown as mean + SD. P-values ,0.05 were considered statistically significant.
Results
TIMP-1 concentration in granulosa cell-conditioned medium, follicular fluid and blood serum Follicular fluid of women undergoing IVF/ICSI treatment revealed high amounts of TIMP-1 (Fig. 1) . Similar high amounts were observed in blood serum of these women. We also showed that TIMP-1 is secreted by endothelial cells as well as by granulosa cells. Under the culturing conditions described above, the incubation of HUVECs and granulosa cells led to much lower TIMP-1 concentrations in the culture supernatants after 4 days when compared with follicular fluid and blood serum.
Regulation of sVEGFR-1 secretion by GCC
Endothelial cells grown in EBM-2 medium containing increasing amounts of 60-fold concentrated serum-free granulosa cellconditioned medium were observed to secrete increasing amounts of sVEGFR-1 (Fig. 2a) . Although the addition of 1.1% GCC to the medium led to no significant cellular response, the addition of 3.3%, 5.4% and 7.6% GCC to the culture medium resulted in significant 1.4-to 1.8-fold increases in endothelial sVEGFR-1 production in comparison to HUVECs grown in pure EBM-2. Furthermore, with 5.4% Figure 1 Mean amount of TIMP-1 in native follicular fluid (FF) and blood serum (BS) as well as in endothelial cell-(HUVEC) and granulosa cell-conditioned medium (GCC) after 4 days of culturing. In follicular fluid and blood serum, a much higher TIMP-1 concentration was found than in the supernatant of cultured cells. For this experiment, follicular fluid, blood serum and conditioned medium, respectively, of 10 different patients were used. sVEGFR-1 secretion regulated by TIMP-1 GCC in the culture medium, the maximum cellular sVEGFR-1 stimulation was reached since 7.6% GCC in the medium led to no further increase in endothelial sVEGFR-1 production.
In this experiment, incubation of HUVECs with EBM-2 culture medium containing 5.4% of 60-fold concentrated serum-free GCC led to a significant 2-fold increase in sVEGFR-1 concentration compared with HUVECs incubated with EBM-2 alone (Fig. 2b) . However, endothelial cells treated with 5.4% ultra-filter flow through showed no differences in sVEGFR-1 concentration in comparison to untreated HUVECs. In contrast, treatment of GCC with ConA coupled to Sepharose led to a significant 33% decrease in the amount of sVEGFR-1 in the supernatant of endothelial cells when compared with the supernatant content of untreated HUVECs grown in pure EBM-2.
Proteins in GCC
Serum-free GCC in a 30-fold concentration comprises a multitude of proteins which were separated by SDS-PAGE according to their size and seen as faint bands after Coomassie staining (Fig. 3) . Four glycosylated proteins containing glycosyl and/or mannosyl residues were enriched and isolated by ConA chromatography. The strongest protein band with an apparent molecular size between 28 and 29 kDa was identified by mass spectrometry and Mascot search as TIMP-1.
Stimulation of endothelial sVEGFR-1 secretion by TIMP-1
Incubation of HUVECs with culture medium containing increasing concentrations of recombinant human TIMP-1 also led to significant increases in cellular sVEGFR-1 secretion (Fig. 4) . Endothelial cells cultured in EBM-2 medium supplemented only with 10 ng/ml TIMP-1 showed no difference in sVEGFR-1 production compared with cells cultured in EBM-2 alone. However, the incubation of endothelial cells either with 20, 30, 40 ng or 50 ng/ml TIMP-1, respectively, resulted in dose-dependent significant 1.4-to 2.2-fold increases in sVEGFR-1 concentration in the culture supernatant when compared with the amount of sVEGFR-1 in the culture supernatant of untreated cells.
Effect of VEGF and TIMP-1 on HUVEC proliferation and sVEGFR-1 secretion
In a 72-h XTT proliferation/inhibition assay, culture medium supplemented with VEGF stimulated HUVEC proliferation to a 3.3-fold maximum in comparison to pure culture medium (Fig. 5a ). When VEGF-treated endothelial cells were co-incubated with TIMP-1 for Figure 2 Mean sVEGFR-1 concentration in supernatant of HUVECs incubated with pure or modified GCCs. (A) HUVECs were cultured in EBM-2 containing increasing amounts of untreated granulosa cell-conditioned medium (GCC, 1.1%, 3.3%, 5.4% or 7.6%) or grown in pure EBM-2 for 4 days. The addition of 3.3% or more GCC to the culture medium resulted in significant increases in endothelial sVEGFR-1 production. (B) sVEGFR-1 production in endothelial cells cultured with 5.4% untreated GCC is significantly increased. Although treatment with 5.4% ultra-filter flow through (FT) showed no effect on the amount of secreted sVEGFR-1, the addition of 5.4% TIMP-1-depleted GCC (by ConA-coupled Sepharose) to the culture medium significantly reduced sVEGFR-1 secretion of endothelial cells compared with cells grown in pure medium (*P , 0.05). Data represent the mean + SD of three separate experiments performed in triplicate (a) or in duplicate (b). Furthermore, sVEGFR-1 production in endothelial cells cultured for 72 h in EBM-2 medium containing VEGF was significantly increased by 1.8-fold when compared with cells cultured in pure medium (Fig. 5b) . After co-incubation with TIMP-1, a further significant 1.3-fold increase in sVEGFR-1 concentration in the culture supernatant of VEGFstimulated HUVECs was found when compared with the supernatant of cells incubated only with VEGF.
TIMP-1 and sVEGFR-1 concentrations in endothelial cell supernatant after TIMP-1 knockdown
Endothelial cells were transfected with four small hairpin RNAs (shRNAs) targeting the human TIMP-1 gene after being cleaved into small interfering RNAs by the cellular machinery (Fig. 6a) . After 4 days of culturing, the TIMP-1 concentration was quantified in the culture supernatant by ELISA. Transfection of the shRNA constructs C1-4 resulted in significant TIMP-1 reductions between 65% and 78% in comparison to endothelial cells cultured in EBM-2 medium alone. HUVECs transfected either with a construct containing a non-effective GFP sequence or the expression vector alone were used as negative controls and showed similar quantities of TIMP-1 in the culture supernatant to untreated control endothelial cells.
After 4 days of incubation, the amount of sVEGFR-1 in HUVEC culture supernatant was also significantly decreased between 42% and 72% in the presence of one of the four gene-specific shRNAs C1-4 in contrast to HUVECs grown in EBM-2 without treatment (Fig. 6b) . Consistent with the TIMP-1 production, both negative controls showed neither stimulation nor inhibition of sVEGFR-1 production compared with untreated endothelial cells.
Discussion
As demonstrated here, TIMP-1 significantly enhances sVEGFR-1 production in human endothelial cells. It is known that granulosa cells produce several factors involved in the regulation of angiogenesis, including VEGF and TIMP-1 (Gruemmer et al., 2005a; Phan et al., 2006) . Although VEGF is essential for corpus luteum angiogenesis and promotes blood vessel formation, TIMP-1 plays an important role in the regulation of tissue remodeling and MMP action in this endocrine gland (Ferrara et al., 1998; Duncan, 2000) and has been shown to effect ovarian steroidogenesis as well (Shores and Hunter, Figure 4 Stimulation of endothelial sVEGFR-1 secretion by recombinant human TIMP-1. HUVECs were cultured in EBM-2 supplemented with increasing amounts of TIMP-1 (10, 20, 30, 40 ng and 50 ng/ml) or grown in pure EBM-2 for 4 days. The addition of 20-50 ng/ml TIMP-1 to the medium resulted in significant increases in sVEGFR-1 in the culture supernatant in a dose-dependent manner when compared with the amount of sVEGFR-1 in the culture supernatant from endothelial cells grown in culture medium alone (*P , 0.05). Data were collected from three separate experiments performed in triplicate. (A) Cells incubated with EBM-2 containing VEGF were significantly increased in number after 72 h when compared with cells incubated with culture medium alone. When TIMP-1 was added to VEGFstimulated HUVECs for 36 of the 72 h, the cell proliferation rate decreased. (B) VEGF in the culture medium also caused an increase in sVEGFR-1 production in endothelial cells after 72 h in comparison to cells grown in pure EBM-2. VEGF-stimulated HUVECs treated with TIMP-1 for 36 of the 72 h, however, produced an additional increase in sVEGFR-1 (*P , 0.05). Data in (a) and (b) were collected from three separate experiments each performed in triplicate.
sVEGFR-1 secretion regulated by TIMP-1 2000). Since granulosa cells are surrounded by follicular fluid, TIMP-1 is also found herein in very large amounts which correspond approximately to blood serum levels (Lahav-Baratz et al., 2003; Reduta et al., 2007) . sVEGFR-1, however, is secreted by micro-as well as macrovascular endothelial cells and appears to be the main modulator for VEGF bioavailability in the female reproductive system (Hornig et al., 2000) . Both cell types also secrete TIMP-1, whereas macrovascular endothelial cells such as HUVECs used in our research produce substantially larger amounts of this protein than do microvascular endothelial cells (Moussiopoulos et al., 1997) . Although granulosa cells, follicular fluid and blood serum were collected from women with higher FSH levels due to their IVF/ICSI treatment (which may have an impact on angiogenesis) rather than from women in untreated ovarian cycles, obvious differences in TIMP-1 concentrations between body fluids and cell culture supernatants should persist.
VEGF and its soluble receptor 1 clearly are key regulators in human ovarian angiogenesis. Although the control of VEGF secretion by various growth factors and cytokines such as platelet-derived growth factor (PlGF)-BB, insulin-like growth factor-1 or interleukin-1 is well known (Ylä-Herttuala et al., 2007) , the regulation of sVEGFR-1 secretion, except under hypoxic conditions in pre-eclampsia by transcription factor HIF-1a (Nagamatsu et al., 2004; Nevo et al., 2006) , bFGF (Barleon et al., 2001) or thrombin (Lockwood et al., 2007) , is still poorly understood. Here, we have shown that a glycosylated factor secreted by granulosa cells into the surrounding culture medium stimulates sVEGFR-1 production in endothelial cells. After partial purification, the protein was identified by mass spectrometry as TIMP-1-a 28.5 kDa glycoprotein. Although TIMP-1 is a low-molecular-weight protein, we achieved concentration by using centrifugal spin devices with 50 kDa molecular weight cut-offs, suggesting that it attaches to other proteins available in the cell culture medium which function either as neutral carriers or modulators of TIMP-1 action.
After confirming the result described above with exogenously added recombinant human TIMP-1, several ways in which this protein effects endothelial sVEGFR-1 secretion can now be investigated. Since sVEGFR-1 is produced by alternative splicing from the membrane VEGF receptor-1 gene, one possibility for TIMP-1 action is to shift the balance between VEGFR-1 and sVEGFR-1 expression in favor of the latter. Recently, it was shown that in leukemic cancer cells, PlGF and VEGF both induce tyrosine phosphorylation of VEGFR-1 and render it susceptible to ectodomain shedding, resulting in the generation of sVEGFR-1 and an intracellular cytoplasmic fragment (Rahimi et al., 2009) . It is not yet clear whether proteolytic shedding also occurs in endothelial cells but it is a possibility for TIMP-1 in controlling the production of sVEGFR-1. In addition, TIMP-1 inhibits the activity of most known MMPs. There is also a good chance that increasing sVEGFR-1 production in endothelial cells is mediated indirectly by an MMP-dependent mechanism. It has been reported that MMP-7 induces HUVEC proliferation (Huo et al., 2002) and also degrades sVEGFR-1 and thus increases VEGF bioavailability around the endothelial cells (Ito et al., 2009) . By inhibiting MMP-7 action, TIMP-1 may prevent sVEGFR-1 degradation and therefore reduce the amount of VEGF and the endothelial cell migration and proliferation. TIMP-1 is described mainly by its properties of being an endogenous MMP inhibitor and thus is a physiological regulator of ECM turnover during embryogenesis, angiogenesis or tissue remodeling, but it also regulates cell growth, proliferation, migration and apoptosis. However, conflicting data have been reported regarding the role of TIMP-1 in cell proliferation. Although TIMP-1 is mitogenic in certain cancer cells and lymphoid cells, it reduces hepatocyte or epithelial cell proliferation. It has also been shown to either promote or inhibit cell proliferation in different experimental settings (Yamada et al., 2001; Chirco et al., 2006) . We found that TIMP-1 has a weak anti-proliferative effect on cultured human macrovascular endothelial cells (HUVECs), although Murphy et al. (1993) first demonstrated that in microvascular endothelial cells, TIMP-1 has no inhibitory effect on cell proliferation. In the meantime, published data not only revealed different MMP and TIMP secretory profiles in microvascular versus macrovascular endothelial cells, but also different responses to VEGF stimulation and overall endothelial cell subtype-specific Figure 6 Mean TIMP-1 and sVEGFR-1 concentrations in endothelial cell culture supernatant after down-regulation of TIMP-1 production. HUVECs were transfected either with one of four gene-specific shRNA constructs (C1 -4) or with two non-specific negative controls (a non-effective GFP sequence and the expression vector alone). Aftergene expression patterns (Jackson and Nguyen, 1997; Bartoli et al., 2003; Viemann et al., 2006) . Furthermore, the weak anti-proliferative response to TIMP-1 treatment suggests an additional mechanism regulating proliferation of macrovascular endothelial cells.
Besides the functions described above, TIMP-1 is also involved in erythropoiesis and steroidogenesis (Lee et al., 2005b; Harslund et al., 2007) . TIMP-1 knockout mice indicate that during the development of the corpus luteum, this protein may play an important role in regulating progesterone production via its ability to regulate ovarian MMP activity and thus intervene in steroidogenesis (Nothnick, 2003) . The function of sVEGFR-1 is supposed to be mainly inhibitory as well, by complexing VEGF and thus reducing its bioavailability. In addition to sequestering the ligand, sVEGFR-1 forms heterodimers with transmembrane VEGFR-2, prevents its autophosphorylation and therefore abolishes signaling (Lamszus et al., 2003) . We showed that media containing TIMP-1 or exogenously added recombinant TIMP-1 led to an increase in sVEGFR-1 secretion by endothelial cells. To verify the role of TIMP-1 in this regulation and to further assess the function of TIMP-1 in ovarian angiogenesis, we used shRNA to silence the TIMP-1 gene in human endothelial cells. Since the inhibition of TIMP-1 by RNA interference led to an inhibition of sVEGFR-1 secretion by endothelial cells as well, we could provide evidence for an interaction between TIMP-1 and sVEGFR-1.
It is known that elevated sVEGFR-1 levels have negative effects on ovarian physiology. Six-fold higher amounts of sVEGFR-1 in serum are found in women with pre-eclampsia, a medical condition with the symptoms of high blood pressure, edema and proteinuria, which remains one of the common causes of maternal death and a major contributor to both maternal and fetal morbidity (Koga et al., 2003) . Also, direct injection of sVEGFR-1 into the pre-ovulatory follicle of rhesus monkeys leads to impaired ovulation and subsequently to impaired development and functional capacity of the primate corpus luteum (Hazzard et al., 2002) . Even cigarette smoking significantly increases sVEGFR-1 concentration in follicular fluid which may result in decreased ovarian vascularization and reduced oocyte maturation, thus negatively affecting female fertility (Motejlek et al., 2006) . Since elevated sVEGFR-1 levels have a negative impact on health and therefore health costs, it is important to gather more knowledge about the regulatory mechanisms of this soluble receptor.
As shown in the present research project, TIMP-1 increases the secretion of sVEGFR-1 of human endothelial cells. This response can be accomplished either on the transcriptional or the signaling level or by direct binding of both proteins. In order to gain insights into this interaction, investigations are in progress.
